Shares of Aurobindo Pharma will be in focus after the company announced that its wholly owned subsidiary, Auro Pharma, has entered into a definitive agreement to acquire the branded non-oncology formulations business of Khandelwal Laboratories for a consideration of Rs 325 crore.
The acquisition will be executed on a slump sale basis and includes a portfolio of established brands across key therapy areas such as pain management, gynaecology, neuropsychiatry, cardio-diabetology, gastroenterology and nutraceuticals. The transaction is aimed at strengthening Aurobindo Pharma’s presence in the Indian branded formulations market, particularly in the chronic and semi-chronic segments.
According to the company, the acquired business has a strong domestic footprint with well-recognised brands and a distribution network spanning multiple regions. The integration of this portfolio is expected to complement Aurobindo Pharma’s existing domestic formulations business and enhance its product offering in non-oncology therapies.
The company stated that the acquisition aligns with its strategy of expanding its India-focused branded portfolio while maintaining capital discipline. The deal is subject to customary regulatory approvals and is expected to be completed within the stipulated timelines.
Aurobindo Pharma has been steadily expanding its presence in the domestic market through selective acquisitions and portfolio additions, while continuing to focus on its global generics and specialty pharmaceutical businesses.
At the time of writing, Aurobindo Pharma shares were trading in line with broader market trends, with investors tracking further updates on deal closure and integration plans.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Comments are closed.